List view / Grid view
The lower carbon propellant has the potential to reduce greenhouse…
The lower carbon propellant has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler by approximately 90 percent, GSK reports.
GSK’s new global headquarters are expected to open in 2024,…
GSK’s new global headquarters are expected to open in 2024, allowing the company to be near London's global life sciences hub.
Trade union body Unite the Union reports that it has…
Trade union body Unite the Union reports that it has successfully secured an additional pay increase for GSK workers after an historic dispute threatened strike action.
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-300x278.jpg)
![The GlaxoSmithKline headquarters building in Brentford, west London, June 2018 [Credit: Willy Barton / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/GSK-3-e1624534468322.jpg)
Tony Wood will assume accountability for R&D across GSK’s portfolio…
Tony Wood will assume accountability for R&D across GSK’s portfolio and pipeline from Dr Hal Barron on 1 August 2022.
GSK announced multi-million renewable energy investment and low carbon inhaler…
GSK announced multi-million renewable energy investment and low carbon inhaler programme in run-up to New York Climate Week.
GSK announces “excellent” Q2 financial performance with growth across all…
GSK announces “excellent” Q2 financial performance with growth across all segments – Pharmaceuticals, Vaccines, Consumer Healthcare.
In an investor update, GlaxoSmithKline (GSK) revealed its plan to…
In an investor update, GlaxoSmithKline (GSK) revealed its plan to promote growth and performance over next ten years.
GSK will use 100 percent renewable electricity usage among other…
GSK will use 100 percent renewable electricity usage among other efforts in its plans to have a net zero impact on the climate by 2030.
Pharma executives are committed to bringing drugs to market to…
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
Sanofi will provide its S protein antigen and GSK will…
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
As part of EPR’s Women in Pharma series, Dr Penny…
As part of EPR’s Women in Pharma series, Dr Penny Heaton, Chief Executive Officer, Bill & Melinda Gates Medical Research Institute, talks to Science Editor Dr Zara Kassam about the need to disrupt global health product development by applying cutting-edge science and technology to combat age-old diseases in the world’s…
